Suppliers / UBE

UBE

Japan 3 duplicate records merged Updated 9 July 2026

UBE is an API manufacturer based in Japan. It holds 3 active US drug master files across a filed portfolio of 27 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 27 October 2023 as NAI.

3
active US DMFs
0
valid CEPs
2
registered plants 2 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 27 October 2023 NAI US FDA
  • 28 September 2017 VAI US FDA
  • 16 September 2016 NAI US FDA
  • 28 January 2015 VAI US FDA
  • 4 November 2011 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Japan, Japan 3002808530
Japan, Japan 3003604942

What they file, and where

Molecule Regulators Docs
Methyl Salicylate PMDA (Japan), US FDA 2
ピタバスタチンカルシウム PMDA (Japan) 2
Bepotastine US FDA 1
Etizolam PMDA (Japan) 1
Felbinac PMDA (Japan) 1
Omidenepag Isopropyl US FDA 1
Silodosin PMDA (Japan) 1
カルブロック PMDA (Japan) 1
クロフェクトン PMDA (Japan) 1
サリチル酸ナトリウム PMDA (Japan) 1
Show all 27 molecules on file
サリメント PMDA (Japan) 1
タスモリン PMDA (Japan) 1
チスタニン PMDA (Japan) 1
ニフラン PMDA (Japan) 1
バイカロン PMDA (Japan) 1
ヒバノンG-20 PMDA (Japan) 1
ピタバスタチンカルシウム水和物 PMDA (Japan) 1
フスタゾール PMDA (Japan) 1
フスタゾール散原末 PMDA (Japan) 1
ベシル酸ベポタスチン PMDA (Japan) 1
メグリン PMDA (Japan) 1
メマンチン塩酸塩精製品(解砕品) PMDA (Japan) 1
メマンチン塩酸塩(粉砕品) PMDA (Japan) 1
レボトミン PMDA (Japan) 1
ロスバスタチンカルシウム PMDA (Japan) 1
塩酸ベバントロール-ウベ PMDA (Japan) 1
日本薬局方ニトレンジピン(製造専用) PMDA (Japan) 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. UBE comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 27 October 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates